Adding antiandrogen to radiotherapy improves survival in recurrent prostate cancer

A nearly two-decades-long clinical trial has demonstrated that adding antiandrogen therapy to radiotherapy can improve the survival of prostate cancer patients who have evidence of disease recurrence after radical prostatectomy. The study conducted by the NRG Oncology Radiation Therapy Oncology Group appears in the February 2 New England Journal of Medicine.